Welcome! This blog contains research, information on lifestyle, nutrition, dietary supplements and health for those with MS, as well as continuing information on the understanding of CCSVI and cerebral hypoperfusion. This blog is informative only--all medical decisions should be discussed with your own physicians.The posts are searchable---simply type in your topic of interest in the search box at the top left.Almost all of MS research is initiated and funded by pharmaceutical companies. This maintains the EAE mouse model and the immune paradigm of MS, and continues the 15 billion dollar a year MS treatment industry. But as we learn more about slowed blood flow, gray matter atrophy, and environmental links to MS progression and disability--all things the current drugs do not address--we're discovering more about how to help those with MS.To learn how this journey began, read my first post from August, 2009. Be well! Joan
Thursday, February 2, 2012
CCSVI and the blood brain barrier--new research
February 2, 2012 at 8:56am
New research is showing us how the blood brain barrier functions. Our understanding of what this barrier is and how it works has changed.
We may not see this happening in our neurologists' offices, or in the press, but it is important to understand that independent researchers (those with no connection to pharma) are looking at how CCSVI impacts the blood brain barrier. I want to share this as encouragement.
This is from an article written by K.K. Jain, MD on Medlink. It was originally released in 1998, but Dr. Jain updates this article, as new research emerges. The last update was in 2011.
And now it includes CCSVI.
Professor Jain is a nanotechnology and neurological expert, and serves as associate editor of Medlink Corporations online encyclopedia of neurology.
For over a century it has been recognized that the entry of certain substances into the brain is restricted. The old concept of the blood-brain barrier as a passive, impermeable barrier that segregates blood and brain interstitial fluid is giving way to the idea that the blood-brain barrier is a dynamic conduit for transport between blood and brain of those nutrients, peptides, proteins, or immune cells that have access to certain transport systems localized within the blood-brain barrier membranes.
When the BBB was first described in the 1800s, it was thought to be an impassible wall between blood, cerebrospinal fluid and brain tissue. But we now understand:
• The blood-brain barrier is an important conduit of nutrients and cells from the blood to the brain.
• It also has an important function in protecting the brain from the entry of harmful substances.
• Knowledge of impairment of permeability of the blood-brain barrier in various neurologic disorders is important in understanding the pathomechanisms and devising strategies for management.
• Permeability of the blood-brain barrier is manipulated for drug delivery to the brain.
Contrast-enhanced MRI in patients with multiple sclerosis show that increased permeability of the blood-brain barrier commonly occurs with this disease. Lymphocyte recruitment into the brain across endothelial cells of the blood-brain barrier, which is otherwise restricted and well regulated, represents a critical event in pathogenesis of multiple sclerosis (Correale and Villa 2007). The changes in capillary permeability often precede T2-weighted MRI evidence of tissue damage. Increased gelatinase B (a type of matrix metalloproteinase) is associated with an open blood-brain barrier on MRI. Steroids may improve capillary function by reducing activity of gelatinase B.
Various inflammatory factors produced by perivascular cells in multiple sclerosis affect the permeability of the blood-brain barrier. One of these, the intercellular adhesion molecule-1, binds to its leukocyte ligands and allows activated leukocytes entry into the central nervous system. According to 1 hypothesis, pathological reflux of venous flow in the cerebral and spinal veins increases the expression of intercellular adhesion molecule-1 by the cerebrovascular endothelium, which, in turn, could lead to increased permeability of the blood-brain barrier (Simka 2009).
Specialists of the blood brain barrier and cerebral endothelium understand CCSVI.
This is why Dr. Berislav Zlokovic, newly appointed chair of the Keck School at USC, was keynote speaker at the first ISNVD conference. CCSVI research makes sense with what these researchers know about the brain and neurodegenerative disease.
It's why Dr. John Cooke of Stanford University and Dr. Stephen Alexander of LSU are both now researching CCSVI and the cerebral endothelium in MS. They both made presentations at the recent ISNVD conference in Orlando.
I hope this gives us all some encouragement.